




King, Valerie A.

From: Oey, Jan
Sent: Monday, February 24, 2003 4:35 PM
To: King, Valerie A.
Subject: FW: EHCJLI/04/03-Menthol Study short term

Sensitivity: Confidential


AA04271_D3_24FEB0
J_Philip Morr...


AA04271_24FEB03_A
TTACHMENTS_Ph...


AA04271_Phillip_Morri
s_AccordM...

-----Original Message-----

From: Michael Szwaneck (402)437-4880 [mailto:Michael.Szwaneck@mdsps.com]
Sent: Monday, February 24, 2003 5:06 PM
To: jan.oey@pmusa.com; martin.unverdorben@pmusa.com;
bettie.l.nelson@pmusa.com; Hans-Juergen.Roethig@pmusa.com;
qiwei.liang@pmusa.com; paul.mendes@pmusa.com
Cc: Megan McCrory; Kimberly Prchal; Robert Earl; Paul Johnson
Subject: EHCJLI/04/03-Menthol Study short term
Sensitivity: Confidential

All,

Attached is draft three protocol and selected attachments dated Feb 24, 2003 for the upcoming 10-day Menthol study for your review. I have incorporated all changes discussed with Jan Oey last Friday (Feb 21). I have also attached a revised ICF for final review.

The IRB date for this study is now March 7. Therefore, I need all documents (protocol, attachments, ICF) final and ready for submission by this Friday, Feb 28, 2003. In order to make these deadlines, please assure that I have comments from legal by Thursday, Feb 27, 2003 at the latest.

Thanks,

Michael F. Szwaneck, Pharm D., MBA
Section Head, Protocol Development and ICFs
MDS Pharma Services - Lincoln, NE
michael.szwaneck@mdsps.com
(402) 437-4880